INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15601, 20884, 'Peginterferon alfa-2a', 'Eye Diseases', 'Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons.  All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders.  Patients should have periodic ophthalmologic exams during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15602, 25815, 'Peginterferon alfa-2a', 'Eye Diseases', 'Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons.  All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders.  Patients should have periodic ophthalmologic exams during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15603, 25816, 'Peginterferon alfa-2a', 'Eye Diseases', 'Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons.  All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders.  Patients should have periodic ophthalmologic exams during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15604, 26243, 'Peginterferon alfa-2a', 'Eye Diseases', 'Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons.  All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders.  Patients should have periodic ophthalmologic exams during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15605, 20060, 'Peginterferon alfa-2a', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15606, 20061, 'Peginterferon alfa-2a', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15607, 20883, 'Peginterferon alfa-2a', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15608, 20884, 'Peginterferon alfa-2a', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15609, 25815, 'Peginterferon alfa-2a', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15610, 25816, 'Peginterferon alfa-2a', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15611, 26243, 'Peginterferon alfa-2a', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15612, 14775, 'Peginterferon beta-1a', 'Liver Diseases', 'Severe hepatic injury, including hepatitis, autoimmune hepatitis, cases of hepatic failure and asymptomatic transient increases in the concentrations of serum transaminases, have been reported in patients treated with beta interferons.  In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury.  The potential risk of these agents used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered before starting therapy, or before starting hepatotoxic drugs.  Patients should be monitored for signs of hepatic injury, including the regular monitoring of liver function tests, and discontinuation of therapy should be considered if serum transaminase levels significantly increase or if hepatic injury occurs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15613, 25748, 'Peginterferon beta-1a', 'Liver Diseases', 'Severe hepatic injury, including hepatitis, autoimmune hepatitis, cases of hepatic failure and asymptomatic transient increases in the concentrations of serum transaminases, have been reported in patients treated with beta interferons.  In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury.  The potential risk of these agents used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered before starting therapy, or before starting hepatotoxic drugs.  Patients should be monitored for signs of hepatic injury, including the regular monitoring of liver function tests, and discontinuation of therapy should be considered if serum transaminase levels significantly increase or if hepatic injury occurs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15614, 25749, 'Peginterferon beta-1a', 'Liver Diseases', 'Severe hepatic injury, including hepatitis, autoimmune hepatitis, cases of hepatic failure and asymptomatic transient increases in the concentrations of serum transaminases, have been reported in patients treated with beta interferons.  In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury.  The potential risk of these agents used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered before starting therapy, or before starting hepatotoxic drugs.  Patients should be monitored for signs of hepatic injury, including the regular monitoring of liver function tests, and discontinuation of therapy should be considered if serum transaminase levels significantly increase or if hepatic injury occurs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15615, 25750, 'Peginterferon beta-1a', 'Liver Diseases', 'Severe hepatic injury, including hepatitis, autoimmune hepatitis, cases of hepatic failure and asymptomatic transient increases in the concentrations of serum transaminases, have been reported in patients treated with beta interferons.  In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury.  The potential risk of these agents used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered before starting therapy, or before starting hepatotoxic drugs.  Patients should be monitored for signs of hepatic injury, including the regular monitoring of liver function tests, and discontinuation of therapy should be considered if serum transaminase levels significantly increase or if hepatic injury occurs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15616, 14775, 'Peginterferon beta-1a', 'Autoimmune Diseases', 'Autoimmune disorders of multiple target organs including idiopathic thrombocytopenia, hyper- and hypothyroidism, and autoimmune hepatitis have been reported with interferon beta.  If patients develop a new autoimmune disorder, consider stopping therapy with this agent.  Care and close monitoring is recommended when prescribing this agent to patients at risk of developing an autoimmune disorder.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15617, 25748, 'Peginterferon beta-1a', 'Autoimmune Diseases', 'Autoimmune disorders of multiple target organs including idiopathic thrombocytopenia, hyper- and hypothyroidism, and autoimmune hepatitis have been reported with interferon beta.  If patients develop a new autoimmune disorder, consider stopping therapy with this agent.  Care and close monitoring is recommended when prescribing this agent to patients at risk of developing an autoimmune disorder.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15618, 25749, 'Peginterferon beta-1a', 'Autoimmune Diseases', 'Autoimmune disorders of multiple target organs including idiopathic thrombocytopenia, hyper- and hypothyroidism, and autoimmune hepatitis have been reported with interferon beta.  If patients develop a new autoimmune disorder, consider stopping therapy with this agent.  Care and close monitoring is recommended when prescribing this agent to patients at risk of developing an autoimmune disorder.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15619, 25750, 'Peginterferon beta-1a', 'Autoimmune Diseases', 'Autoimmune disorders of multiple target organs including idiopathic thrombocytopenia, hyper- and hypothyroidism, and autoimmune hepatitis have been reported with interferon beta.  If patients develop a new autoimmune disorder, consider stopping therapy with this agent.  Care and close monitoring is recommended when prescribing this agent to patients at risk of developing an autoimmune disorder.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15620, 14775, 'Peginterferon beta-1a', 'Heart Failure', 'Congestive heart failure, cardiomyopathy, and cardiomyopathy with congestive heart failure occur in patients receiving interferon beta.  It is recommended to monitor patients with significant cardiac disease for worsening of their cardiac condition during initiation and continuation of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15621, 25748, 'Peginterferon beta-1a', 'Heart Failure', 'Congestive heart failure, cardiomyopathy, and cardiomyopathy with congestive heart failure occur in patients receiving interferon beta.  It is recommended to monitor patients with significant cardiac disease for worsening of their cardiac condition during initiation and continuation of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15622, 25749, 'Peginterferon beta-1a', 'Heart Failure', 'Congestive heart failure, cardiomyopathy, and cardiomyopathy with congestive heart failure occur in patients receiving interferon beta.  It is recommended to monitor patients with significant cardiac disease for worsening of their cardiac condition during initiation and continuation of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15623, 25750, 'Peginterferon beta-1a', 'Heart Failure', 'Congestive heart failure, cardiomyopathy, and cardiomyopathy with congestive heart failure occur in patients receiving interferon beta.  It is recommended to monitor patients with significant cardiac disease for worsening of their cardiac condition during initiation and continuation of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15624, 14775, 'Peginterferon beta-1a', 'Pancytopenia', 'Interferon beta can cause decreased peripheral blood counts in all cell lines, including rare instances of pancytopenia and severe thrombocytopenia.  It is recommended to monitor patients for infections, bleeding, and symptoms of anemia.  Monitor complete blood cell counts, differential white blood cell counts, and platelet counts during treatment.  Close monitoring is recommended when prescribing this agent to patients at risk, in particular to patients with myelosuppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15625, 25748, 'Peginterferon beta-1a', 'Pancytopenia', 'Interferon beta can cause decreased peripheral blood counts in all cell lines, including rare instances of pancytopenia and severe thrombocytopenia.  It is recommended to monitor patients for infections, bleeding, and symptoms of anemia.  Monitor complete blood cell counts, differential white blood cell counts, and platelet counts during treatment.  Close monitoring is recommended when prescribing this agent to patients at risk, in particular to patients with myelosuppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15626, 25749, 'Peginterferon beta-1a', 'Pancytopenia', 'Interferon beta can cause decreased peripheral blood counts in all cell lines, including rare instances of pancytopenia and severe thrombocytopenia.  It is recommended to monitor patients for infections, bleeding, and symptoms of anemia.  Monitor complete blood cell counts, differential white blood cell counts, and platelet counts during treatment.  Close monitoring is recommended when prescribing this agent to patients at risk, in particular to patients with myelosuppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15627, 25750, 'Peginterferon beta-1a', 'Pancytopenia', 'Interferon beta can cause decreased peripheral blood counts in all cell lines, including rare instances of pancytopenia and severe thrombocytopenia.  It is recommended to monitor patients for infections, bleeding, and symptoms of anemia.  Monitor complete blood cell counts, differential white blood cell counts, and platelet counts during treatment.  Close monitoring is recommended when prescribing this agent to patients at risk, in particular to patients with myelosuppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15628, 14775, 'Peginterferon beta-1a', 'Depressive Disorder', 'Depression, suicidal ideation, and suicide have been reported in patients receiving peginterferon beta.  Patients should be monitored for any evidence of depression or other psychiatric symptoms.  Patients should be advised to report any signs or symptoms of depression, or other changes in mood or behavior.  In severe cases, therapy should be stopped immediately and psychiatric intervention should be instituted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15629, 25748, 'Peginterferon beta-1a', 'Depressive Disorder', 'Depression, suicidal ideation, and suicide have been reported in patients receiving peginterferon beta.  Patients should be monitored for any evidence of depression or other psychiatric symptoms.  Patients should be advised to report any signs or symptoms of depression, or other changes in mood or behavior.  In severe cases, therapy should be stopped immediately and psychiatric intervention should be instituted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15630, 25749, 'Peginterferon beta-1a', 'Depressive Disorder', 'Depression, suicidal ideation, and suicide have been reported in patients receiving peginterferon beta.  Patients should be monitored for any evidence of depression or other psychiatric symptoms.  Patients should be advised to report any signs or symptoms of depression, or other changes in mood or behavior.  In severe cases, therapy should be stopped immediately and psychiatric intervention should be instituted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15631, 25750, 'Peginterferon beta-1a', 'Depressive Disorder', 'Depression, suicidal ideation, and suicide have been reported in patients receiving peginterferon beta.  Patients should be monitored for any evidence of depression or other psychiatric symptoms.  Patients should be advised to report any signs or symptoms of depression, or other changes in mood or behavior.  In severe cases, therapy should be stopped immediately and psychiatric intervention should be instituted.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15632, 14775, 'Peginterferon beta-1a', 'Injection Site Reaction', 'Injection site reactions, including injection site necrosis, can occur with the use of subcutaneous interferon beta.  Caution should be exercised when prescribing this agent and the decisions to discontinue therapy following necrosis at a single injection site should be based on the extent of the necrosis.  For patients who continue therapy after injection site necrosis has occurred, it is recommended to avoid administration of this agent near the affected area until it is fully healed and if multiple lesions occur, discontinue therapy until healing occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15633, 25748, 'Peginterferon beta-1a', 'Injection Site Reaction', 'Injection site reactions, including injection site necrosis, can occur with the use of subcutaneous interferon beta.  Caution should be exercised when prescribing this agent and the decisions to discontinue therapy following necrosis at a single injection site should be based on the extent of the necrosis.  For patients who continue therapy after injection site necrosis has occurred, it is recommended to avoid administration of this agent near the affected area until it is fully healed and if multiple lesions occur, discontinue therapy until healing occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15634, 25749, 'Peginterferon beta-1a', 'Injection Site Reaction', 'Injection site reactions, including injection site necrosis, can occur with the use of subcutaneous interferon beta.  Caution should be exercised when prescribing this agent and the decisions to discontinue therapy following necrosis at a single injection site should be based on the extent of the necrosis.  For patients who continue therapy after injection site necrosis has occurred, it is recommended to avoid administration of this agent near the affected area until it is fully healed and if multiple lesions occur, discontinue therapy until healing occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15635, 25750, 'Peginterferon beta-1a', 'Injection Site Reaction', 'Injection site reactions, including injection site necrosis, can occur with the use of subcutaneous interferon beta.  Caution should be exercised when prescribing this agent and the decisions to discontinue therapy following necrosis at a single injection site should be based on the extent of the necrosis.  For patients who continue therapy after injection site necrosis has occurred, it is recommended to avoid administration of this agent near the affected area until it is fully healed and if multiple lesions occur, discontinue therapy until healing occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15636, 14775, 'Peginterferon beta-1a', 'Kidney Diseases', 'Pharmacokinetic studies have shown that renal impairment can increase the Cmax of Peginterferon beta-1a.  Caution should be taken when prescribing this agent to these patients.  It is recommended to monitor renal function, and to monitor for adverse reactions due to increased drug exposure in patients with severe renal impairment.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15637, 25748, 'Peginterferon beta-1a', 'Kidney Diseases', 'Pharmacokinetic studies have shown that renal impairment can increase the Cmax of Peginterferon beta-1a.  Caution should be taken when prescribing this agent to these patients.  It is recommended to monitor renal function, and to monitor for adverse reactions due to increased drug exposure in patients with severe renal impairment.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15638, 25749, 'Peginterferon beta-1a', 'Kidney Diseases', 'Pharmacokinetic studies have shown that renal impairment can increase the Cmax of Peginterferon beta-1a.  Caution should be taken when prescribing this agent to these patients.  It is recommended to monitor renal function, and to monitor for adverse reactions due to increased drug exposure in patients with severe renal impairment.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15639, 25750, 'Peginterferon beta-1a', 'Kidney Diseases', 'Pharmacokinetic studies have shown that renal impairment can increase the Cmax of Peginterferon beta-1a.  Caution should be taken when prescribing this agent to these patients.  It is recommended to monitor renal function, and to monitor for adverse reactions due to increased drug exposure in patients with severe renal impairment.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15640, 14775, 'Peginterferon beta-1a', 'Seizures', 'The use of peginterferon beta-1a may cause seizures.  Exercise caution when prescribing this agent to patients with a history of seizure disorders.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15641, 25748, 'Peginterferon beta-1a', 'Seizures', 'The use of peginterferon beta-1a may cause seizures.  Exercise caution when prescribing this agent to patients with a history of seizure disorders.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15642, 25749, 'Peginterferon beta-1a', 'Seizures', 'The use of peginterferon beta-1a may cause seizures.  Exercise caution when prescribing this agent to patients with a history of seizure disorders.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15643, 25750, 'Peginterferon beta-1a', 'Seizures', 'The use of peginterferon beta-1a may cause seizures.  Exercise caution when prescribing this agent to patients with a history of seizure disorders.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15644, 14775, 'Peginterferon beta-1a', 'Thrombotic Microangiopathies', 'Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, some fatal, have been reported with interferon beta products.  Discontinue therapy if clinical symptoms and laboratory findings are consistent with TMA, and manage as clinically indicated.  Care should be taken when prescribing this agent to patients at risk of endothelial injury.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15645, 25748, 'Peginterferon beta-1a', 'Thrombotic Microangiopathies', 'Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, some fatal, have been reported with interferon beta products.  Discontinue therapy if clinical symptoms and laboratory findings are consistent with TMA, and manage as clinically indicated.  Care should be taken when prescribing this agent to patients at risk of endothelial injury.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15646, 25749, 'Peginterferon beta-1a', 'Thrombotic Microangiopathies', 'Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, some fatal, have been reported with interferon beta products.  Discontinue therapy if clinical symptoms and laboratory findings are consistent with TMA, and manage as clinically indicated.  Care should be taken when prescribing this agent to patients at risk of endothelial injury.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15647, 25750, 'Peginterferon beta-1a', 'Thrombotic Microangiopathies', 'Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, some fatal, have been reported with interferon beta products.  Discontinue therapy if clinical symptoms and laboratory findings are consistent with TMA, and manage as clinically indicated.  Care should be taken when prescribing this agent to patients at risk of endothelial injury.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15648, 0, 'Pentazocine', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15649, 0, 'Pentazocine', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15650, 0, 'Pentazocine', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15651, 0, 'Pentazocine', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15652, 0, 'Pentazocine', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15653, 0, 'Pentazocine', 'Myocardial Infarction', 'Opiate partial agonists may increase systemic and pulmonary arterial pressure and systemic vascular resistance, particularly when given by intravenous administration.  Data are available for pentazocine and butorphanol.  Therapy with opiate partial agonists should be administered cautiously and only if the benefit justifies the risk in patients with acute myocardial infarction (especially if accompanied by hypertension or left ventricular failure) or coronary insufficiency.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15654, 0, 'Pentazocine', 'Substance-Related Disorders', 'Opiate partial agonists have the potential to cause dependence and abuse, particularly in patients with a history of drug abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use, and abrupt cessation or a significant reduction in dosage may precipitate withdrawal symptoms.  Because of their opiate antagonistic effect, withdrawal symptoms may also occur if opiate partial agonists are administered to patients with an opiate dependence or in whom substantial amounts of narcotics have recently been administered.  Therapy with opiate partial agonists is not recommended in patients who are physically dependent on narcotics.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate partial agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15655, 0, 'Pentazocine', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate partial agonists can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Unless mechanical ventilation is provided, extreme caution is advised when opiate partial agonists are given to patients head injury, intracranial lesions, or a preexisting elevated CSF pressure.  Also, clinicians treating such patients should be aware that opiate partial agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15656, 0, 'Pentazocine', 'Respiratory Insufficiency', 'Opiate partial agonists may produce respiratory depression by decreasing respiratory drive and increasing airway resistance.  A "ceiling effect" has been noted for these agents, and increasing doses do not produce proportional or further respiratory depression.  However, the duration of effect is prolonged.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate partial agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS or respiratory depression; acute alcohol intoxication; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate partial agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression.  However, in the case of buprenorphine, naloxone may not be effective due to buprenorphine''s slow rate of dissociation from mu receptors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15657, 0, 'Pentazocine', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15658, 0, 'Pentazocine', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15659, 0, 'Pentazocine', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15660, 0, 'Pentazocine', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15661, 0, 'Pentazocine', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15662, 0, 'Pentazocine', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15663, 0, 'Pentostatin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15664, 0, 'Pentostatin', 'Bone Marrow Failure Disorders', 'Pentostatin can induce myelosuppression, primarily during the initial courses of therapy.  Disease status, including a bone marrow examination, should be determined if severe neutropenia continues.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, bleeding or symptoms of anemia.  Therapy with pentostatin should be administered cautiously in patients with bone marrow suppression.  Close clinical monitoring of hematopoietic function is necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15665, 0, 'Pentostatin', 'Kidney Diseases', 'Pentostatin is primarily eliminated by the kidney and is a nephrotoxic drug.  Approximately 90% of pentostatin is excreted as unchanged drug and/or metabolites in the urine.  Pentostatin clearance is reduced and half-life is increased considerably in patients with moderate renal impairment.  Patients with impaired renal function should be treated only when the potential benefit justifies the potential risk.  Therapy should be administered cautiously and close clinical monitoring of renal function is recommended prior to initiating therapy and before each dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15666, 0, 'Pentamidine', 'Cardiovascular Diseases', 'Parenteral use of pentamidine may be associated with serious and potentially fatal cardiovascular effects.  Sudden and severe hypotension, cardiorespiratory arrest, ventricular tachycardia, torsade de pointes, ECG abnormalities, and facial flushing have been reported.  Therapy with pentamidine should be administered cautiously in all patients but in particular, those with preexisting hypotension, severe cardiovascular disease, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Patients should be in a supine position and blood pressure monitored closely during and after administration of the drug until blood pressure is stable.  Equipment for emergency resuscitation should be readily available if the parenteral route is used.  ECGs should also be performed before, during, and after parenteral therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15667, 0, 'Pentamidine', 'Dehydration', 'Patients who are dehydrated may be particularly susceptible to the nephrotoxic and hypotensive effects associated with the parenteral use of pentamidine.  Dehydration should preferably be corrected prior to initiation of therapy.  In patients who may be at risk for dehydration, such as those with severe and/or prolonged diarrhea or vomiting, fluid status and blood pressure should be monitored closely.  If signs of renal irritation develop during therapy, hydration should be increased as indicated, accompanied by a reduction in dosage if necessary.  Therapy should be withdrawn if urinary output decreases progressively or azotemia increases.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15668, 0, 'Pentamidine', 'Diabetes Mellitus', 'Pentamidine may have direct toxic effects on beta cells of the pancreas.  Hypoglycemia, which may be severe and/or prolonged, as well as hyperglycemia and insulin-dependent diabetes mellitus, the latter of which may be irreversible, have been reported.  The onset of pentamidine-induced hypoglycemia generally varied from 5 to 7 days after start of therapy to several days after therapy stops.  In some cases, hyperglycemia and progression to diabetes followed, although these effects have occurred independently also.  Pancreatic toxicity has been reported with both parenteral use and, less frequently, oral inhalation of pentamidine.  The risk appears to be related to total cumulative dosage and prior therapy with the drug, particularly within the last 3 months.  Therapy with pentamidine, regardless of route of administration, should be administered cautiously in patients with or predisposed to diabetes or spontaneous hypoglycemia.  Blood glucose should be monitored more closely during and for some time after pentamidine therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15669, 0, 'Pentamidine', 'Hematologic Diseases', 'Hematologic toxicities have been associated occasionally with the parenteral use of pentamidine.  Leukopenia and, less frequently, thrombocytopenia have been reported and may be severe (e.g., leukocyte count < 1000/mm3, platelet count < 20,000/mm3).  Anemia, neutropenia, pancytopenia, and prolonged clotting time have occurred rarely.  Therapy with pentamidine should be administered cautiously in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts, including platelets, should be performed prior to and periodically during and after therapy.  Marked depression of blood counts may be indication for withdrawal of pentamidine therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15670, 0, 'Pentamidine', 'Pancreatitis', 'Acute and potentially fatal pancreatitis has been reported with parenteral use and, rarely, oral inhalation of pentamidine.  Patients with a history of or known risk factors for pancreatitis, such as alcohol abuse or hypertriglyceridemia, should be monitored closely during therapy with pentamidine.  Therapy should be discontinued at the first signs or symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15671, 0, 'Pentamidine', 'Kidney Diseases', 'Parenteral use of pentamidine may be associated with nephrotoxicity, usually evidenced by elevations in BUN or serum creatinine concentrations.  Azotemia has also been reported.  Although pentamidine-induced nephrotoxicity is generally mild to moderate in severity and reversible following discontinuation of the drug, acute renal failure has occurred occasionally.  Limited evidence suggests that nephrotoxicity may occur more frequently in patients with AIDS and may be accompanied by severe, sometimes life-threatening hyperkalemia.  Therapy with pentamidine should be administered cautiously in patients with renal impairment.  The need for dosage adjustments is uncertain.  To minimize the risk of toxicity, patients should be adequately hydrated and use with other nephrotoxic agents should be avoided.  Renal function and serum potassium levels should be closely monitored, and the dosing frequency reduced or therapy withdrawn if toxicity develops.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15672, 0, 'Pentamidine', 'Asthma', 'Orally inhaled pentamidine may induce bronchospasm and cough.  Therapy with aerosolized pentamidine should be administered cautiously in patients with severe bronchospastic disease or a history of extensive smoking.  Pretreatment with a beta-2 adrenergic bronchodilator prior to each dose of aerosolized pentamidine may be helpful in patients who experience respiratory symptoms from the medication.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15673, 0, 'Pentamidine', 'Liver Diseases', 'Parenteral use of pentamidine may cause elevated liver function tests.  Therapy with pentamidine should be administered cautiously in patients with hepatic impairment.  Serum transaminase, alkaline phosphatase, and bilirubin levels should be measured periodically, and the dosing frequency reduced or therapy withdrawn if significant elevations develop.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15674, 0, 'Pentobarbital', 'Alcoholic Intoxication', 'The use of barbiturates is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of barbiturates may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with barbiturates should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15675, 0, 'Pentobarbital', 'Substance-Related Disorders', 'Barbiturates have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages.  Abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance to a barbiturate, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with barbiturates.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of barbiturates should be undertaken gradually using a dosage-tapering schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15676, 0, 'Pentobarbital', 'Liver Diseases', 'Barbiturates are extensively metabolized by the liver.  The plasma clearance of barbiturates may be decreased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with barbiturates should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Barbiturates are not recommended for use in patients with cirrhosis, hepatic failure, hepatic coma, or other severe hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15677, 0, 'Pentobarbital', 'Porphyrias', 'The use of barbiturates is contraindicated in patients with a history of porphyria.  Barbiturates may exacerbate acute intermittent porphyria or porphyria variegata by inducing the enzymes responsible for porphyrin synthesis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15678, 0, 'Pentobarbital', 'Exanthema', 'Skin eruptions may precede rare but potentially fatal barbiturate-induced reactions such as systemic lupus erythematosus and exfoliative dermatitis, the latter of which may be accompanied by hepatitis and jaundice.  Therapy with barbiturates should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to barbiturates.  Barbiturate therapy should be withdrawn promptly at the first sign of a dermatologic adverse effect.  However, cutaneous reactions may proceed to an irreversible stage even after cessation of medication due to the slow rate of metabolism and excretion of barbiturates.  Patients should be advised to promptly report signs that may indicate impending development of barbiturate-related cutaneous lesions, including high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Rashes may be more likely to occur with phenobarbital and mephobarbital.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15679, 0, 'Pentobarbital', 'Respiratory Insufficiency', 'Barbiturates may produce severe respiratory depression, apnea, laryngospasm, bronchospasm and cough, particularly during rapid intravenous administration.  In usual hypnotic dosages, the degree of respiratory depression produced is similar to that which occurs during physiologic sleep, while at higher dosages, the rate, depth and volume of respiration may be markedly decreased.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with barbiturates should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Barbiturates, especially injectable formulations, should generally be avoided in patients with sleep apnea, hypoxia, or severe pulmonary diseases in which dyspnea or obstruction is evident.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15680, 0, 'Pentobarbital', 'Cardiovascular Diseases', 'The intravenous administration of barbiturates may produce severe cardiovascular reactions such as bradycardia, hypertension, or vasodilation with fall in blood pressure, particularly during rapid infusion.  Parenteral therapy with barbiturates should be administered cautiously in patients with hypertension, hypotension, or cardiac disease.  The intravenous administration of barbiturates should be reserved for emergency treatment of acute seizures or for anesthesia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15681, 0, 'Pentobarbital', 'Hypotension', 'Barbiturates should not be administered by injection to patients in shock or coma or who have recently received another respiratory depressant.  The hypnotic and hypotensive effects of these agents may be prolonged and intensified in such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15682, 0, 'Pentobarbital', 'Adrenal Insufficiency', 'Barbiturates, especially phenobarbital, secobarbital and butabarbital, may diminish the systemic effects of exogenous and endogenous corticosteroids via induction of hepatic microsomal enzymes, thereby accelerating the metabolism of corticosteroids.  In addition, barbiturates may interfere with pituitary corticotropin production.  Therapy with barbiturates should be administered cautiously in patients with adrenal insufficiency.  Patients with borderline hypoadrenalism should be monitored closely, and patients receiving steroid supplementation may require an adjustment in dosage when barbiturates are added to or withdrawn from their medication regimen.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15683, 0, 'Pentobarbital', 'Depressive Disorder', 'Barbiturates depress the central nervous system and may cause or exacerbate mental depression.  Therapy with barbiturates should be administered cautiously in patients with a history of depression or suicidal tendencies.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15684, 0, 'Pentobarbital', 'Hematologic Diseases', 'Hematologic toxicity, including agranulocytosis, thrombocytopenic purpura and megaloblastic anemia, has been reported rarely during use of barbiturates.  Therapy with barbiturates should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Blood counts are recommended prior to and periodically during long-term therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, easy bruising, petechiae, bleeding, pallor, dizziness, or jaundice.  Barbiturate therapy should be discontinued if blood dyscrasias occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15685, 0, 'Pentobarbital', 'Osteomalacia', 'Rickets and osteomalacia have rarely been reported following prolonged use of barbiturates, possibly due to increased metabolism of vitamin D as a result of enzyme induction by barbiturates.  Long-term therapy with barbiturates should be administered cautiously in patients with vitamin D deficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15686, 0, 'Pentobarbital', 'Psychotic Disorders', 'Paradoxical reactions characterized by excitability and restlessness may occur in pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with barbiturates.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15687, 16931, 'Penicillamine', 'Bone Marrow Failure Disorders', 'The use of penicillamine is contraindicated in patients with a history of penicillamine-related aplastic anemia or agranulocytosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15688, 25939, 'Penicillamine', 'Bone Marrow Failure Disorders', 'The use of penicillamine is contraindicated in patients with a history of penicillamine-related aplastic anemia or agranulocytosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15689, 16931, 'Penicillamine', 'Kidney Diseases', 'Penicillamine is considerably excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  The use of penicillamine is contraindicated in patients with renal dysfunction.  Proteinuria and/or hematuria may develop during therapy and may lead to nephrotic syndrome.  Monitoring for proteinuria and hematuria is recommended.  Caution should be taken and routine monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15690, 25939, 'Penicillamine', 'Kidney Diseases', 'Penicillamine is considerably excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  The use of penicillamine is contraindicated in patients with renal dysfunction.  Proteinuria and/or hematuria may develop during therapy and may lead to nephrotic syndrome.  Monitoring for proteinuria and hematuria is recommended.  Caution should be taken and routine monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15691, 16931, 'Penicillamine', 'Liver Diseases', 'Cases of intrahepatic cholestasis and toxic hepatitis have been reported with the use of penicillamine.  Care should be taken and liver function tests are recommended every six months for the duration of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15692, 25939, 'Penicillamine', 'Liver Diseases', 'Cases of intrahepatic cholestasis and toxic hepatitis have been reported with the use of penicillamine.  Care should be taken and liver function tests are recommended every six months for the duration of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15693, 16931, 'Penicillamine', 'Myasthenia Gravis', 'The use of penicillamine has been associated with fatalities due to certain diseases such as Goodpasture''s syndrome, and myasthenia gravis.  Caution is advised in patients with these conditions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15694, 25939, 'Penicillamine', 'Myasthenia Gravis', 'The use of penicillamine has been associated with fatalities due to certain diseases such as Goodpasture''s syndrome, and myasthenia gravis.  Caution is advised in patients with these conditions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15695, 16931, 'Penicillamine', 'Asthma', 'Penicillin products should be used with caution in individuals with histories of significant allergies and/or asthma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15696, 25939, 'Penicillamine', 'Asthma', 'Penicillin products should be used with caution in individuals with histories of significant allergies and/or asthma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15697, 0, 'Perampanel', 'Kidney Diseases', 'Perampanel should be used with caution in patients with moderate renal impairment, and slower titration may be considered.  No dose adjustment is required in patients with mild renal impairment.  Care should be taken when prescribing this agent in patients with renal impairment, and close monitoring of renal function is recommended.  The use of perampanel in patients with severe renal impairment or patients undergoing hemodialysis is not recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15698, 0, 'Perampanel', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15699, 0, 'Perampanel', 'Hypertriglyceridemia', 'Increased levels of triglycerides have occurred in patients using perampanel.  Care should be taken when prescribing this agent to patients with high triglycerides levels, and close monitoring of lipid profile is recommended during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15700, 0, 'Perampanel', 'Weight Gain', 'Weight gain has occurred with the use of perampanel.  Care should be taken when prescribing this agent to patients predisposed to weight gain, and regular monitoring of weight is recommended.', '2', '', 'DDInter', 0);
